Results Simplified PESI scores could be calculated in 4, of the 4, randomized patients; of those, Among patients with simplified PESI scores of 0 or 1, fatal PE, all-cause mortality, and other adverse outcomes were uncommon within the first 7, 14, and 30 days. Acute PE is a potentially life-threatening medical emergency that requires urgent intervention. In the United States, most patients with PE are admitted to the hospital, whereas patients with acute DVT are often managed as outpatients with coordinated care through a primary provider. Current standard therapy for most patients with acute PE or DVT is the same: anticoagulation therapy with a parenteral agent e.
|Published (Last):||6 August 2011|
|PDF File Size:||10.15 Mb|
|ePub File Size:||4.19 Mb|
|Price:||Free* [*Free Regsitration Required]|
Print Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy i. The rate of major bleeding was significantly lower with rivaroxaban than with standard anticoagulant therapy. Although effective, treatment with warfarin requires frequent blood tests and is thus burdensome for patients. Specifically, treatment with rivaroxaban alone was non-inferior to standard therapy in preventing recurrent thromboembolism HR 1.
Rivaroxaban use was also linked with significantly fewer major bleeding events when compared with standard therapy. Eligible patients were those who had an acute, symptomatic PE with or without symptomatic deep-vein thrombosis DVT.
Patients were randomized to receive rivaroxaban, or standard therapy consisting of enoxaparin with either warfarin or acenocoumarol. The primary efficacy outcome was recurrent venous thromboembolism i. Rivaroxaban was non-inferior to standard therapy in preventing recurrent venous thromboembolism post-PE HR 1. The rate of major bleeding was also lower in the rivaroxaban group, as compared to standard therapy HR 0.
All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.
Among patients with acute PE, is rivaroxaban noninferior to warfarin in preventing recurrent VTE or bleeding? Bottom Line Among patients with acute PE, rivaroxaban is noninferior to warfarin in preventing recurrent VTE, and is associated with similar bleeding rates. At a mean follow-up of 7 months, rivaroxaban was noninferior to standard therapy in terms of the rate of recurrent symptomatic VTE 2. Like the others, it employed a noninferiority rather than a superiority design, and enrolled a relatively heterogeneous patient population.
Print Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy i. The rate of major bleeding was significantly lower with rivaroxaban than with standard anticoagulant therapy. Although effective, treatment with warfarin requires frequent blood tests and is thus burdensome for patients.